All News
Filter News
Found 978 articles
-
Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense
1/11/2024
Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has secured an indefinite-delivery, indefinite-quantity (IDIQ) procurement contract with a maximum value up to $235.8 million to supply BioThrax ® (Anthrax Vaccine Adsorbed) for use by all branches of the U.S. military as Pre-Exposure Prophylaxis (PrEP) for anthrax disease.
-
Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024
1/9/2024
Emergent BioSolutions today announced that Haywood Miller, Interim Chief Executive Officer and Rich Lindahl, Chief Financial Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024, at 9:00 a.m. PT.
-
OneOne Biosciences Partners with Ginkgo Bioworks to Advance its Platform and Nitrogen Fixation Microbial Product
12/20/2023
OneOne Biosciences, a French startup building a comprehensive suite of agricultural microbial solutions for farmers, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new partnership.
-
Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted)
11/28/2023
Emergent BioSolutions Inc. (NYSE: EBS) today announced that the Biomedical Advanced Research and Development Authority (BARDA) within the Administration for Strategic Preparedness and Response at the United States Department of Health and Human Services has awarded a $75 million option to Emergent’s existing contract (HHSO100201600030C) for the acquisition of newly licensed anthrax vaccine CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted).
-
Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing
11/24/2023
Emergent BioSolutions Inc. (NYSE: EBS) today confirmed that on November 16, 2023, the New York Stock Exchange (NYSE) sent a notice that the company is not in compliance with Section 802.01E of the NYSE Listed Company Manual due to a delay in filing its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023.
-
Soligenix Announces Recent Accomplishments And Third Quarter 2023 Financial Results
11/13/2023
Soligenix, Inc. announced today its recent accomplishments and financial results for the quarter ended September 30, 2023.
-
Emergent BioSolutions Reports Third Quarter 2023 Financial Results
11/8/2023
Emergent BioSolutions Inc. (NYSE: EBS) today reported selected financial results for the third quarter ended September 30, 2023.
-
Calidi Biotherapeutics Announces Key Leadership Promotions and New Board Appointment
11/1/2023
Calidi Biotherapeutics, Inc. today announced two key promotions from the clinical leadership team and the appointment of a new Board Director.
-
UPDATE: Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 8, 2023
10/30/2023
Emergent BioSolutions Inc. has rescheduled its conference call to Wednesday, November 8, at 5:00 pm eastern time to discuss the financial results for the third quarter of 2023, recent business developments, and financial outlook for full year 2023.
-
Novozymes accelerates growth in Q3 and is on track to deliver on full-year expectations
10/26/2023
October 26, 2023. Novozymes delivers 5% organic sales growth, an EBIT-margin of 25.5% before special items, and ROIC including goodwill of 16.3% before special items in the first nine months of the 2023 financial year.
-
Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 2, 2023
10/19/2023
Emergent BioSolutions Inc. will host a conference call on Thursday, November 2, 2023, at 5:00 pm eastern time to discuss the financial results for the third quarter of 2023, recent business developments, and financial outlook for full year 2023.
-
Myricx Expands its Leadership Team with the Appointment of Dr. Robert McLeod as VP Clinical Development
9/13/2023
Myricx Bio announces the appointment of Dr. Robert McLeod as Vice President Clinical Development.
-
Emergent BioSolutions’ NARCAN® Nasal Spray Launches Over the Counter Making it Possible for Everyone to Help Save a Life from an Opioid Overdose Emergency
8/30/2023
Emergent BioSolutions Inc. announced NARCAN® Naloxone HCl Nasal Spray 4 mg will be available on shelves nationwide and online beginning in September.
-
Soligenix Announces Recent Accomplishments And Second Quarter 2023 Financial Results
8/21/2023
Soligenix, Inc. announced today its recent accomplishments and financial results for the quarter ended June 30, 2023.
-
Novozymes delivers results within expectations in the first half of 2023 and narrows the full year outlook
8/9/2023
Novozymes delivers 3% organic sales growth, an EBIT-margin of 25% before special items, and ROIC including goodwill of 17% before special items in the first half of the 2023 financial year.
-
Emergent BioSolutions Announces Strategic Steps to Strengthen Core Business and Financial Position
8/8/2023
Emergent BioSolutions (NYSE: EBS) today announced it is reducing investment in and de-emphasizing focus on growth in its CDMO services business.
-
Emergent BioSolutions Reports Financial Results for Second Quarter 2023
8/8/2023
Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the second quarter ended June 30, 2023. It also announced strategic steps to reduce investment in and de-emphasize focus on growth in its CDMO business.
-
Bavarian Nordic Receives USD 120 Million Contract for the Manufacturing of Smallpox and Mpox Vaccine from the U.S. Government
8/3/2023
Bavarian Nordic A/S announced that the U.S. Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services, has placed a new order valued at USD 120 million, primarily covering the manufacturing of new bulk product for the Company’s smallpox/mpox vaccine.
-
Emergent BioSolutions Awarded 10-Year BARDA Contract Valued at up to a Maximum of $704 Million for Advanced Development and Procurement of Ebanga™ Treatment for Ebola
7/31/2023
Emergent BioSolutions Inc. announced that it was awarded a 10-year contract by the BARDA, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, valued at up to a maximum of $704 million, for advanced development, manufacturing scale-up, and procurement of Ebanga™, a licensed treatment for Ebola virus disease.
-
Emergent BioSolutions to Release Second Quarter 2023 Financial Results and Conduct Conference Call on August 8, 2023
7/25/2023
Emergent BioSolutions Inc. will host a conference call on Tuesday, August 8, 2023, at 5:00 pm eastern time to discuss the financial results for the second quarter of 2023, recent business developments, revenue guidance for the third quarter of 2023, and financial outlook for full year 2023.